All News

20 June 2012

Galaxy Biotech to Regain Worldwide Rights to HuL2G7, a Clinical Stage Humanized Monoclonal Antibody Against HGF for Treatment of CancerAntibodies

18 June 2012

Spectrum Pharmaceuticals Announces Outstanding ZEVALIN® Clinical Data In Aggressive Relapsed/Refratory Lymphoma; Presented at the 17th Congress of the European Hematology AssociationAntibodies

15 June 2012

GLYCOTOPE Moves PankoMab Towards Phase-II Clinical DevelopmentAntibodies

14 June 2012

Millennium Highlights Updated Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Patients with Relapsed or Refractory Hodgkin LymphomaAntibodies

14 June 2012

DiaMedica Announces Summary of DM-204 Program at the 72nd Annual American Diabetes Association ConferenceAntibodies

14 June 2012

Immunomedics Reports Updated Results From Phase I Pretargeting Therapy Study in Colorectal CancerAntibodies

14 June 2012

Theraclone Sciences Announces Initiation of a Phase 1 Clinical Trial of TCN-202, an Antibody in Development for the Treatment of Human Cytomegalovirus InfectionAntibodies

14 June 2012

Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United StatesAntibodies

13 June 2012

Immunomedics Develops Potential New Treatment Regimen for Non-Hodgkin LymphomaAntibodies

13 June 2012

Actinium Pharmaceuticals Treats First Patients in Multicenter Phase 1/2 Leukemia Trial of Actimab-A(TM)Antibodies

12 June 2012

Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA (alemtuzumab) for Multiple SclerosisAntibodies

9 June 2012

FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast CancerAntibodies

6 June 2012

Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Peripheral SpondyloarthritisAntibodies

6 June 2012

Novartis Phase III study showed 62% of patients with most severe form of childhood arthritis were symptom-free with ACZ885 treatmentAntibodies

6 June 2012

New Phase 3 Data Show SIMPONI® Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs And Symptoms In Patients With Active DiseaseAntibodies

6 June 2012

New Phase 3 Data Show STELARA® Significantly Reduced Signs And Symptoms Of Active Psoriatic ArthritisAntibodies

6 June 2012

ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These AgentsAntibodies

6 June 2012

MorphoSys Antibody Reaches Major Milestone in Collaboration with RocheAntibodies

6 June 2012

Roche’s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapyAntibodies

5 June 2012

Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions of the BENEFIT and BENEFIT-EXT Clinical Trials of NULOJIX (belatacept)Antibodies

5 June 2012

Five Prime Therapeutics Announces that Human Genome Sciences Files U.S. IND for HGS1036/FP-1039 FGF Ligand TrapAntibodies

5 June 2012

Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate CancerAntibodies

5 June 2012

ThromboGenics and BioInvent To Regain Full Rights to TB-403Antibodies

5 June 2012

ThromboGenics and BioInvent Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402Antibodies

4 June 2012

ImmunoGen, Inc. Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast CancerAntibodies

4 June 2012

ImmunoGen, Inc. Announces Presentation of New Clinical Data for SAR3419Antibodies

3 June 2012

Genentech Data Showed That People With Metastatic Colorectal Cancer Lived Longer When They Continued on Avastin Plus ChemotherapyAntibodies

3 June 2012

Genentech’s Targeted Investigational Breast Cancer Medicine, Trastuzumab Emtansine (T-DM1), Reduced the Risk of Cancer Worsening or Death by 35 Percent in Pivotal Phase III TrialAntibodies

2 June 2012

Genentech Study Showed That Adding Avastin to Chemotherapy Cut the Risk of the Disease Getting Worse in Difficult-to-Treat Recurrent Ovarian Cancer by HalfAntibodies

2 June 2012

Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1 Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell CancerAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Aflibercept (Eylea) Biosimilars Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

PD-1 Agonists Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Nectin-4-Targeted Immunotherapy Pipeline Review

CD73 Inhibitor Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities